Aptahem
BioStock-article: Aptahem comments on the paused phase I study
Read the full interview with Mikael Lindstam at biostock.se:
https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.
Datum | 2023-07-24, kl 15:49 |
Källa | Cision |
![](https://static.allaaktier.se/ads/hand-waving-2.png)